Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of Hemay005 in moderate to severe active ulcerative colitis
CTR20261765Phase 3Active
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mufemilast in autoimmune colitis, sponsored by Hemay Pharmaceutical Technology. Started Aug 2026; status: active.
02
Drugs
mufemilast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20261765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261765.